Company profile: Imagion Biosystems
1.1 - Company Overview
Company description
- Provider of molecularly targeted magnetic nanoparticles (MagSense) for cancer detection, developing imaging agents for solid tumors to aid diagnosis and staging, and conducting a Phase 1 HER2 breast cancer lymph node study aiming to avoid biopsies. Offers PrecisionMRX nanoparticles for MRI, hyperthermia, and magnetic particle imaging; supplies SPIONs with multiple coatings and nanoparticles for third-party biomedical applications.
Products and services
- Diagnostic Imaging Services: Architects creation of MagSense imaging agents for various solid tumors to aid diagnosis, staging, and prognosis, leveraging molecularly targeted magnetic nanoparticle systems
- MagSense Imaging Agent Technology: Develops molecularly targeted magnetic nanoparticles that attach to cancer cells and act as magnetic beacons, enabling cancer detection via MagSense imaging agents
- MagSense Phase 1 Study – HER2 Breast Cancer: Conducts a Phase 1 clinical trial of the MagSense HER2 imaging agent to detect breast cancer spread to lymph nodes, aiming to avoid biopsies.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Imagion Biosystems
Immedica
HQ: Sweden
Website
- Description: Provider of niche/specialty care pharmaceutical products with commercial coverage across Europe and the Middle East. Portfolio includes Akynzeo for prevention of chemotherapy-induced nausea and vomiting; Ammonaps for urea cycle disorders; Arlevert for vertigo and tinnitus; Loargys for Arginase 1 Deficiency; Neofordex high-dose dexamethasone; and Nor-NOHA Blood Collection Tubes for blood collection and diagnostic purposes.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Immedica company profile →
Alethia Biotherapeutics
HQ: Canada
Website
- Description: Provider of monoclonal antibody-based therapeutics for cancer-associated diseases, including AB-16B5, a humanized IgG2 antibody targeting secreted clusterin to inhibit EMT, enhance chemotherapy response, and reduce tumor invasion; AB-3A4, developed as an ADC targeting KAAG1 for ovarian and triple-negative breast cancers; and STAR technology for discovering differentially expressed mRNA sequences, including rare ones, to identify novel therapeutic targets.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alethia Biotherapeutics company profile →
Trethera
HQ: United States
Website
- Description: Provider of small-molecule therapeutics that control DNA replication and integrity, including TRE-515, an orally bioavailable inhibitor of deoxycytidine kinase (dCK) targeting the nucleotide salvage pathway to treat solid tumors and autoimmune diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Trethera company profile →
Onco-NX
HQ: United Kingdom
Website
- Description: Provider of drug discovery research dedicated to identifying new promising anticancer agents as a University of Salford spin-out company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Onco-NX company profile →
LadRx
HQ: United States
Website
- Description: Provider of biopharmaceutical therapeutics leveraging LADR (Linker Activated Drug Release) technology to bind anti-cancer molecules to albumin and release cytotoxic payloads at tumors, enabling higher doses with minimized off-target toxicity. Portfolio includes Aldoxorubicin, next-generation LADR-7, and Arimoclomol to amplify heat-shock proteins against protein misfolding, aggregation, and lysosomal dysfunction.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full LadRx company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Imagion Biosystems
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Imagion Biosystems
2.2 - Growth funds investing in similar companies to Imagion Biosystems
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Imagion Biosystems
4.2 - Public trading comparable groups for Imagion Biosystems
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →